drugset / Trial / NCT01957176
A Rollover Study to Provide Continued Treatment With Eltrombopag
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The objective of this study was to provide continued treatment with eltrombopag for subjects who were participating in a Novartis-sponsored investigational study with eltrombopag (parent studies 114968/ASPIRE (NCT01440374), PMA112509 (NCT00903422), and TRA105325/EXTEND (NCT00351468), receiving clinical benefit without unacceptable toxicity and to collect long-term safety data.
Timeline
- Start
- 2013-10-15
- Primary completion
- 2022-02-23
- Completion
- 2022-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | 12.5 mg | Oral |
| Subject | Eltrombopag | Small molecule | 25 mg | Oral |
| Subject | Eltrombopag | Small molecule | 50 mg | Oral |
| Subject | Eltrombopag | Small molecule | 75 mg | Oral |
| Subject | Eltrombopag | Small molecule | 100 mg | Oral |
| Subject | Eltrombopag | Small molecule | 150 mg | Oral |
| Subject | Eltrombopag | Small molecule | 300 mg | Oral |